06.11.25 -- Formulation Is Key For Y-mAbs' Self-Assembling Antibody

Mitigate risk upfront to maximize significant first mover advantage over later drug entrants. Explore the untapped potential for injectable generic drug growth and three priorities for maximizing speed to market.

Explore regulatory framework and expectations, and see the benefit of a comprehensive approach to CCI tailored for mAbs and complex modalities such as fusion proteins or bioconjugates.

Common fill-finish risks include human error, process variability, contamination, product inconsistency, and more. Explore best-practice solutions for manufacturers looking to de-risk this process.

discover insights into how innovative connectors streamline workflows, save time, and enhance reliability in critical applications, ultimately supporting improved outcomes in cell and gene therapies.

The biopharmaceutical industry faces growing downstream processing challenges in purifying complex biologics efficiently and at scale.

Discover cutting-edge antibody purification resins designed to tackle challenges in purifying novel therapeutic formats like bispecific antibodies and Fc-fusion proteins with high efficiency.

Explore how the oligonucleotide therapeutics market is advancing with scalable solutions for high-purity purification, supporting global production of life-changing RNA therapies.

Two post–Protein A capture two-step mAb processes were developed and compared to an archetypical three-step mAb purification process using two IEX steps after Protein A capture.

It’s time to look at how new protein A technologies may replace resin-based methods and enable more productive and flexible purification.